Cost‐effectiveness of Add‐on Therapy with Pregabalin in Patients with Refractory Partial Epilepsy

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Epilepsia

• Publication date

  2008-03-01

• Fields of study

  Medicine, Economics

• Identifiers
  DOI 10.1111/j.1528-1167.2007.01279.xPMID 17822431
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Economic evaluation of levetiracetam as an add-on therapy in patients with refractory epilepsy

  2012cited by this paper
• The impact of seizures and adverse effects on global health ratings.

  2007cited by this paper
• National Institute for clinical excellence preoperative tests: Is the consensus hard to get?: 1AP3-9

  2007cited by this paper
• Validity and Responsiveness of Generic Preference-based HRQOL Instruments in Chronic Epilepsy

  2006influential reference
• Assessing the Cost-Effectiveness of New Pharmaceuticals in Epilepsy in Adults: The Results of a Probabilistic Decision Model

  2005cited by this paper
• Adverse effects of antiepileptic drugs

  2005cited by this paper
• Cost-effectiveness of add-on lamotrigine therapy in clinical practice.

  2005cited by this paper
• Pregabalin Add‐on Treatment: A Randomized, Double‐blind, Placebo‐controlled, Dose–Response Study in Adults with Partial Seizures

  2004cited by this paper
• Dose-response trial of pregabalin adjunctive therapy in patients with partial seizures

  2003cited by this paper
• PNP15 EVALUATION OF THE RELATIONSHIP BETWEEN EPILEPSY SEVERITY AND UTILITY

  2002cited by this paper
• PNP8 ADJUNCTIVE TOPIRAMATE THERAPY IN PATIENTS WITH REFRACTORY SEIZURES:A LIFETIME COST-UTILITY ANALYSIS

  2002cited by this paper
• Mortality Risk N Children with Epilepsy: The Dutch Study of Epilepsy in Childhood

  2001influential reference
• Adverse Effects of Antiepileptic Drugs

  2000cited by this paper
• Representing Both First- and Second-order Uncertainties by Monte Carlo Simulation for Groups of Patients

  2000cited by this paper
• Uncertainty in Decision Models Analyzing Cost-Effectiveness

  2000cited by this paper
• Early identification of refractory epilepsy.

  2000cited by this paper
• Patients with refractory seizures.

  1999cited by this paper
• Adjunctive therapy in epilepsy: a cost-effectiveness comparison of two AEDs.

  1999cited by this paper
• Adjunctive lamotrigine therapy in patients with refractory seizures: a lifetime cost–utility analysis

  1998influential reference
• Uncertainty in Decision Models Analyzing Cost-Effectiveness

  1998influential reference
• Cost-effectiveness model of adjunctive lamotrigine for the treatment of epilepsy

  1998cited by this paper
• The New Antiepileptic Drugs: A Systematic Review of Their Efficacy and Tolerability

  1997cited by this paper
• New antiepileptic drugs: a systematic review of their efficacy and tolerability

  1996influential reference
• THE EPIDEMIOLOGY OF EPILEPSY: Past, Present, and Future

  1996cited by this paper
• Adjunctive therapy in epilepsy: a cost-effectiveness comparison of alternative treatment options.

  1995influential reference
• RBRVS: is there a solution to Medicare physician payment problems?

  1989cited by this paper
• Facts about epilepsy.

  1972cited by this paper
• Facts about epilepsy.

  1972cited by this paper

• Oral versus Intravenous Iron for Anemia in Pregnancy: A Cost-Effectiveness Analysis

  2023cites this paper
• An economic evaluation of vagus nerve stimulation as an adjunctive treatment to anti-seizure medications for the treatment of drug-resistant epilepsy in England

  2021cites this paper
• Cost-utility model of brivaracetam in the adjunctive treatment of patients with epilepsy in Spain

  2020cites this paper
• Cost-utility analysis of alemtuzumab in comparison with interferon beta, fingolimod, and natalizumab treatment for relapsing-remitting multiple sclerosis in Austria

  2019cites this paper
• Assessment of components included in published societal perspective or QALY outcome economic analyses for antiepileptic drug treatment in chronic epilepsy

  2018cites this paper
• Health technology assessment in epilepsy: moving towards patient-centered, efficient care

  2017cites this paper
• A systematic review of the effectiveness of policies restricting access to pregabalin

  2017cites this paper
• Estimating Quality Adjusted Life Years and Willingness to Pay Values for Microbiological Foodborne Disease (Phase 2)

  2017cites this paper
• A systematic review of economic evaluations of treatments for patients with epilepsy

  2017cites this paper
• Welfare cost of childhood- and adolescent-onset epilepsy: A controlled national study.

  2016cites this paper
• Coste-utilidad de asenapina frente a olanzapina para el tratamiento de los episodios maniacos de pacientes con trastorno bipolar tipo I

  2015cites this paper
• Pharmacoeconomic Outcomes for Pregabalin: A Systematic Review in Neuropathic Pain, Generalized Anxiety Disorder, and Epilepsy from a Spanish Perspective

  2014cites this paper
• The management of lower urinary tract symptoms in men

  2014cites this paper
• Healthcare Utilization and Expenditure Associated with Newly Diagnosed Epilepsy among Seniors of Arizona Medicaid Beneficiaries

  2013cites this paper
• Cost‐effectiveness of single‐dose tamsulosin and dutasteride combination therapy compared with tamsulosin monotherapy in patients with benign prostatic hyperplasia in the UK

  2013cites this paper
• Retigabine as add‐on treatment of refractory epilepsy – a cost‐utility study in a Swedish setting

  2013cites this paper
• New drugs for the treatment of epilepsy: a practical approach.

  2013cites this paper
• The Cost Effectiveness of Newer Epilepsy Treatments

  2012influential citation
• The social and economic consequences of epilepsy: A controlled national study

  2011cites this paper
• Randomized, double-blind, placebo-controlled trial of ezogabine (retigabine) in partial epilepsy

  2011cites this paper
• Pharmacoeconomics of anti-epileptic drugs as adjunctive therapy for refractory epilepsy

  2010cites this paper
• Cost-utility analysis of rufinamide versus topiramate and lamotrigine for the treatment of children with Lennox-Gastaut Syndrome in the United Kingdom.

  2010cites this paper
• 240 Pharmacoeconomics of Epilepsy Treatment

  2010cites this paper
• Concordance of survey and billing data in a study of outpatient healthcare cost and utilization among epilepsy patients.

  2009cites this paper
• New and investigational antiepileptic drugs

  2009cites this paper
• Cost-effectiveness of pregabalin versus venlafaxine in the treatment of generalized anxiety disorder: findings from a Spanish perspective

  2009cites this paper
• Pregabalin in the management of partial epilepsy

  2009cites this paper
• [Drug regimens in patients with medication-resistant epilepsy in neurology and epilepsy outpatient departments in Spain].

  2008cites this paper